Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Creative Commons License

Eskazan A. E., Keskin D.

Therapeutic advances in hematology, vol.8, pp.237-243, 2017 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2017
  • Doi Number: 10.1177/2040620717719851
  • Journal Name: Therapeutic advances in hematology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), EMBASE, Directory of Open Access Journals
  • Page Numbers: pp.237-243
  • Keywords: bosutinib, chronic myeloid leukemia, dasatinib, imatinib, nilotinib, ponatinib, radotinib, tyrosine kinase inhibitor, TYROSINE KINASE INHIBITORS, CHROMOSOME-POSITIVE LEUKEMIAS, BCR-ABL, CYTOGENETIC RESPONSES, IMATINIB, INTOLERANCE, RESISTANCE, BCR-ABL1, THERAPY, DASATINIB
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University-Cerrahpasa Affiliated: Yes